The effect of parenchymal liver disease on the disposition and elimination of sedatives and analgesics.
D000700:Analgesics / Q000378:metabolism*; D014151:Anti-Anxiety Agents / Q000378:metabolism; D001463:Barbiturates / Q000378:metabolism; D003975:Diazepam / Q000378:metabolism; D006207:Half-Life; D006505:Hepatitis / Q000378:metabolism; D006801:Humans; D006993:Hypnotics and Sedatives / Q000378:metabolism*; D008099:Liver / Q000378:metabolism*; D008103:Liver Cirrhosis / Q000378:metabolism; D008107:Liver Diseases / Q000378:metabolism*; D008111:Liver Function Tests; D008614:Meperidine / Q000378:metabolism; D009294:Narcotics / Q000378:metabolism; D010634:Phenobarbital / Q000378:metabolism
D000700:Analgesics; D014151:Anti-Anxiety Agents; D001463:Barbiturates; D006993:Hypnotics and Sedatives; D009294:Narcotics; D008614:Meperidine; D003975:Diazepam; D010634:Phenobarbital